<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>877</ReferenceId>
        <DateLastUpdated>2020-09-30-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11003481</PubmedId>
            <Abstract>The effects of monoclonal antibody (MAb) C179 recognizing a conformational epitope in the middle of the hemagglutinine (HA) stem region were examined in a mouse model in the experiments of prevention and treatment of lethal bronchopneumonia caused by influenza A virus of H5 subtype. To model the lethal infection, avian nonpathogenic strain A/mallard duck/Pennsylvania/10218/84 (H5N2) was adapted to mice. This resulted in highly pathogenic pneumovirulent mouse-adapted (MA) variant, which was characterized. Three amino acid changes were found in the HA1 subunit of HA of MA virus. One of these was located inside the region of the conformational epitope recognized by MAb C179. However, this substitution was not significant for the recognition of HA and virus neutralization by MAb C179 in vitro and in vivo. Intraperitoneal administration of two different concentrations of MAb C179 one day before or two days after the virus challenge significantly decreased mortality rate. These results suggest that MAb C179 is efficient not only in the prevention and treatment of H1 and H2 influenza virus bronchopneumonia, as was reported previously, but also of H5-induced bronchopneumonia as well, and demonstrate in vivo the existence of a common neutralizing epitope in the HAs of these three subtypes.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>1733-41</ArticlePages>
            <ArticleTitle>Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Smirnov</LastName>
                    <ForeName>Y A</ForeName>
                </Author>
                <Author>
                    <LastName>Lipatov</LastName>
                    <ForeName>A S</ForeName>
                </Author>
                <Author>
                    <LastName>Gitelman</LastName>
                    <ForeName>A K</ForeName>
                </Author>
                <Author>
                    <LastName>Claas</LastName>
                    <ForeName>E C</ForeName>
                </Author>
                <Author>
                    <LastName>Osterhaus</LastName>
                    <ForeName>A D</ForeName>
                </Author>
            </Authors>
            <Affiliations>The D.I. Ivanovsky Institute of Virology RAMS, Moscow, Russia.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Epitopes;Hemagglutinin Glycoproteins, Influenza Virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(pharmacology; therapeutic use); Antibodies, Viral(pharmacology; therapeutic use); Bronchopneumonia(prevention &amp; control; therapy; virology); Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Epitopes(genetics; immunology); Hemagglutinin Glycoproteins, Influenza Virus(genetics; immunology); Influenza A Virus, H5N2 Subtype; Influenza A virus(drug effects; genetics; immunology); Mice; Molecular Sequence Data; Neutralization Tests; Pneumonia, Viral(prevention &amp; control; therapy; virology); Sensitivity and Specificity</ArticleMeshHeadingsList>
            <Journal>
                <Volume>145</Volume>
                <Issue>8</Issue>
                <Title>Archives of virology</Title>
                <Issn>1432-8798</Issn>
                <MedlineTa>Arch Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA epitope</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>T331, G332, P333, R334, N335, G389, I390, T391, N392, K393, V394, N395, S396, I397, I398, D399, K400</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAF04719.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>95888</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>177377</EpitopeId>
                <ReferenceRegion>HA1: T318, G319, P320, R321, N322, HA2: G47, I48, T49, N50, K51, V52, N53, S54, I55, I56, D57, K58</ReferenceRegion>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>This H5 HA molecule is from a mouse-adapted variant of the wt PA/10218/84 HA, which has 3 substitutions: S203F, E273G and L320P. This epitope is conserved among subtypes H1, H2 and H5, except for HA1:P320L, HA2:I55V and HA2:D57E, in H2 and H1 subtypes and HA1:T318I in H2 subtype. Epitope positions in the article are by H3 numbering system.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1964914</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>223935</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 320 HA units at months 0, 1, 3 and 6.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Details about the generation of mAb C179 are found in Okuno et al, J Virol. 1993 67(5):2552 [PMID:7682624].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>In vitro neutralization of mouse adapted (MA) black dk/NJ/78 by epitope-specific mAb C179 is shown to be similar, albeit higher, to neutralization of H5 subtype Influenza virus, while H7 subtype is not neutralized, as previously described. These results suggest that the reactivity for H5 subtype is not affected by mutations that arose during adaptation in mouse, even when (as L320P) in the epitopic region for this mAb.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>C179</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Mouse-adapted black dk/NJ/78-MA</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1166624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>9919</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>223935</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 320 HA units at months 0, 1, 3 and 6.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Details about the generation of mAb C179 are found in Okuno et al, J Virol. 1993 67(5):2552 [PMID:7682624].</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000654</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Ascitic Fluid</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>C179</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG2a</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Mice received the mAb (1 mg) i.p. as prevention (24 hs prior) or treatment (48 hs post) from virus challenge.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>20</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Death is completely prevented by challenge with a pathogenic mouse-adapted variant of the source species by 1 day prior injection of 1 mg of epitope-specific mAb. With 0.1 mg, 90% survival is seen, while control animals are all dead by 13 days after the challenge. Similar numbers, although at lower percentages, of surviving animals are seen when the mAb is administered 2 days after infection.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Mouse-adapted PA/10218/84</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>95888</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1964911</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>223935</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 320 HA units at months 0, 1, 3 and 6.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Details about the generation of mAb C179 are found in Okuno et al, J Virol. 1993 67(5):2552 [PMID:7682624].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>In vitro neutralization of mouse adapted (MA) PA (H5) virus by epitope-specific mAb C179 is shown to be similar, albeit lower, to neutralization of H2 subtype Influenza virus, while H7 subtype is not neutralized, as previously described. These results suggest that the reactivity for H5 subtype is not affected by mutations that arose during adaptation in mouse, even when (as L320P) in the epitopic region for this mAb.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>C179</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Mouse-adapted PA/10218/84</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>95888</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1964912</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>223935</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 320 HA units at months 0, 1, 3 and 6.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Details about the generation of mAb C179 are found in Okuno et al, J Virol. 1993 67(5):2552 [PMID:7682624].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The radioimmunoprecipitation of MDCK cells infected with mouse adapted (MA) ) lack dk/NJ/78 (H2) or H5 and H7 viruses by epitope-specific mAb C179 show it precipitated the H5 HA as efficiently as the H2 HA and failed to react with H7 subtype strain.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>C179</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Mouse-adapted black dk/NJ/78-MA</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1166624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <InfectedCell>
                                    <SubType>Infected Cell</SubType>
                                    <SourceOrganismId>9615</SourceOrganismId>
                                </InfectedCell>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1964909</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>223935</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 320 HA units at months 0, 1, 3 and 6.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Details about the generation of mAb C179 are found in Okuno et al, J Virol. 1993 67(5):2552 [PMID:7682624].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The radioimmunoprecipitation of MDCK cells infected with mouse adapted (MA) PA (H5) or H2 and H7 viruses by epitope-specific mAb C179 show it precipitated the H5 HA as efficiently as the H2 HA and failed to react with H7 subtype strain.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>C179</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Mouse-adapted PA/10218/84</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>95888</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <InfectedCell>
                                    <SubType>Infected Cell</SubType>
                                    <SourceOrganismId>9615</SourceOrganismId>
                                </InfectedCell>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

